Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. Patients and Methods: The present study focused on the treatment and outcomes of breast cancer patients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). Results: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75%) had had primary invasive lobular carcinoma. Of the 40 patients, 82% had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95% confidence interval, 16.8-38.3 months). Conclusion: Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.

Original languageEnglish
JournalClinical Breast Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2017
Externally publishedYes

Fingerprint

Breast Neoplasms
Lobular Carcinoma
Gastrointestinal Tract
Neoplasm Metastasis
Ductal Carcinoma
Gastrointestinal Endoscopy
Therapeutics
Observation
Databases
Hormones
Confidence Intervals
Pathology
Bone and Bones
Lung
Survival
Liver
Brain
Neoplasms

Keywords

  • Estrogen receptor
  • Gastrointestinal metastasis
  • GI
  • Lobulare carcinoma
  • MBC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{79a1348d957742eda1e464c964bd149a,
title = "Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes",
abstract = "Introduction: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. Patients and Methods: The present study focused on the treatment and outcomes of breast cancer patients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). Results: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75{\%}) had had primary invasive lobular carcinoma. Of the 40 patients, 82{\%} had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95{\%} confidence interval, 16.8-38.3 months). Conclusion: Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.",
keywords = "Estrogen receptor, Gastrointestinal metastasis, GI, Lobulare carcinoma, MBC",
author = "Emilia Montagna and Sara Pirola and Patrick Maisonneuve and {De Roberto}, Giuseppe and Giuseppe Cancello and Antonella Palazzo and Giuseppe Viale and Marco Colleoni",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2017.07.003",
language = "English",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement

T2 - Features and Outcomes

AU - Montagna, Emilia

AU - Pirola, Sara

AU - Maisonneuve, Patrick

AU - De Roberto, Giuseppe

AU - Cancello, Giuseppe

AU - Palazzo, Antonella

AU - Viale, Giuseppe

AU - Colleoni, Marco

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. Patients and Methods: The present study focused on the treatment and outcomes of breast cancer patients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). Results: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75%) had had primary invasive lobular carcinoma. Of the 40 patients, 82% had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95% confidence interval, 16.8-38.3 months). Conclusion: Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.

AB - Introduction: Metastatic breast cancer typically involves the lungs, bones, brain, and liver and only occasionally affects the gastrointestinal (GI) tract. The relevant published data have been limited to case reports and small series of patients. Patients and Methods: The present study focused on the treatment and outcomes of breast cancer patients with GI involvement diagnosed at the European Institute of Oncology. We analyzed the clinicopathologic features of the GI metastases and compared them with those of the primary tumors according to their histologic type (ductal or lobular carcinoma). Results: From the database of the Department of Pathology, 40 patients who had undergone endoscopy or GI surgery with a final diagnosis of metastatic breast cancer from 2000 to 2014 were identified. The greatest proportion of patients (75%) had had primary invasive lobular carcinoma. Of the 40 patients, 82% had hormone receptor-positive disease in the metastatic lesion; 34 patients were candidates for systemic therapy. The median length of observation after GI metastasis was 18 months (range, 0.6-79 months). The overall survival from the diagnosis of GI involvement was 33 months (95% confidence interval, 16.8-38.3 months). Conclusion: Lobular breast carcinoma has a greater propensity to metastasize to the GI tract compared with other breast cancer subtypes. In the presence of GI symptoms, even if nonspecific, the GI tract should be thoroughly studied. Systemic treatment, including hormonal therapy, should be considered.

KW - Estrogen receptor

KW - Gastrointestinal metastasis

KW - GI

KW - Lobulare carcinoma

KW - MBC

UR - http://www.scopus.com/inward/record.url?scp=85026515810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026515810&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2017.07.003

DO - 10.1016/j.clbc.2017.07.003

M3 - Article

AN - SCOPUS:85026515810

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -